Why Biohaven Rallied: Vyglxia Gets Another FDA Review

Executive Summary

Biohaven rallied sharply on October 22, 2026, after disclosing that the FDA accepted its resubmitted application for Vyglxia, or troriluzole, in spinocerebellar ataxia. The agency assigned a first-quarter 2027 decision goal and plans an advisory committee meeting. These developments appear in the company’s filing and were corroborated by The Fly.

Matching late-session snapshots showed BHVN at $14.69, up 25.02%. That observation comes from Nexqual and Investing.com; it should be read as an attributed snapshot because closing data differed across vendors.

Our assessment is cautiously constructive on the regulatory opportunity. The resubmission creates another chance for approval, while leaving the substantive evidence decision ahead.

Why This Matters

The prior rejection concerned the foundation of the efficacy case: real-world evidence, external controls, potential bias and unmeasured confounding. Those concerns are described in Biohaven’s rejection announcement and NeurologyLive’s background review.

For shareholders, the central question is whether the additional analyses address those weaknesses convincingly. An advisory meeting could make that debate more visible, including the strongest objections to approval.

The Thesis

The favorable interpretation is that Vyglxia again has a defined regulatory process. Our inference is that this increases the relevance of an asset investors could previously have discounted heavily.

The investment case still requires evidence that can survive regulatory scrutiny. Acceptance establishes that a review will proceed; the outcome remains uncertain.